Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01394627 · ClinicalTrials.gov registry record · NA
Hypoglycemia and the Mineralocorticoid Receptor
A NA study of Hypoglycemia, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT01394627 is a NA study of Hypoglycemia that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 21 participants, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01394627, a NA study of Hypoglycemia, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to look at whether blockade of the mineralocorticoid receptor will result in changes in the cardiovascular and inflammatory response to hypoglycemia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Eplerenone
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-01 |
| Est. Completion | 2016-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01394627
The ClinicalTrials.gov registry entry for NCT01394627 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (96% lower). The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hypoglycemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01394627 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01394627 about?
NCT01394627 is a clinical study titled "Hypoglycemia and the Mineralocorticoid Receptor". The purpose of this study is to look at whether blockade of the mineralocorticoid receptor will result in changes in the cardiovascular and inflammatory response to hypoglycemia.
What is the current status of trial NCT01394627?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2011-01. Estimated completion is 2016-08.
What conditions does trial NCT01394627 study?
This clinical trial studies the following conditions: Hypoglycemia.
What interventions are being tested in trial NCT01394627?
The interventions under investigation include: Placebo (DRUG), Eplerenone (DRUG).
Who is sponsoring clinical trial NCT01394627?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01394627 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypoglycemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diabetes Clinical Decision Support
RECRUITING · NA
-
Effect of Fasting on Hypoglycemic Counterregulation in Type 1 Diabetes
RECRUITING · NA
-
Enhancing Shared Decision-making to Guide Care for People With Dementia and Diabetes
RECRUITING · NA
-
Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation
RECRUITING · NA
-
Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes
RECRUITING · NA
-
Monitoring Exhaled Breath to Noninvasively Detect Glycemic Events
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.